Studies of the impact of experimental inoculation of Alzheimer brain homogenates in mice usually focus only on β-amyloid and tau lesions, but do not reveal consequences of inoculations on clinical signs, neuronal alterations or cerebral atrophy, despite the importance of these signs for Alzheimer’s disease. The gene discussed is MAPT; the disease is Alzheimer disease.